LAT antibody
Principal name
LAT antibody
Alternative names for LAT antibody
pp36, p36-38, 36 kDa Phospho-Tyrosine Adapter Protein, Linker For Activation of T-Cells Family Member 1
Ncbi ID
NP_001014987.1, NP_001014987, 9606, 10116, NM_001014987, NP_034819.1, NM_010689, NM_014387, NM_001014988
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Paraffin Sections (P), Western blot / Immunoblot (WB), Immunocytochemistry/Immunofluorescence (ICC/IF), Immunoprecipitation (IP), Flow Cytometry (F)
Background of LAT antibody
This LAT.10-17 (10-17) monoclol antibody reacts with human Linker for Activation of T cells (LAT), which is essential for T cell receptor (TCR)-mediated sigl transduction. Characterized as an integral transmembrane protein, this ~37-kDa molecule does not possess a true extracellular domain. Upon TCR/CD3 engagement, LAT localizes to lipid rafts and is tyrosine phosphorylated by ZAP-70, leading to the recruitment and activation of other downstream sigling molecules such as Grb-2, PLCγ, and PI3K. This adapter molecule has been shown to be required for T cell activation, as well as thymocyte and T regulatory cell development. In humans, LAT is expressed on peripheral blood lymphocytes, lymph nodes, and tonsil. Studies in mice have shown that LAT is expressed in thymocytes, T cells, mast cells, tural killer cells, megakaryocytes, platelets, and early B cells. This antibody does not crossreact with the mouse antigen.
General readings
Paz PE., et al. (2001) Biochem J. 356(2):461-71.Zhang W., et al. (1998) Cell. 92(1):83-92.
Figure 1B. Distribution of LAT and NTAL on rat basophilic leukemia cells.
Figure 1A. Distribution of LAT and NTAL in separate clusters on mast cell plasma membrane sheets. LAT and NTAL were detected on mouse bone marrow-derived mast cells (BMMC; Figure 1A) and RBL rat basophilic leukemia cell line Figure 1B by anti-LAT (LAT-1D1) and polyclonal anti-NTAL antibody (AP03007PU-N), followed by 5 or 10 nm gold-conjugated secondary antibodies, respectively.
IHC Image of AM20572PU-NHuman Thymus: Formalin-Fixed, Paraffin-Embedded (FFPE)
IHC Image of AM20572PU-NHuman Tonsil: Formalin-Fixed, Paraffin-Embedded (FFPE)
Western Blot of 10e6 normal peripheral human blood cells (lane 1), Jurkat (lane 2), and C57BL/6 splenocytes (lane 3) with 5 µg/mL anti-human LAT antibody (AM20572PU-N). Bands were visualized using HRP-conjugated rat anti-mouse IgG.
Western blot (WB) analysis of LAT antibody (Cat.-No.: AP06532PU-N) in extracts from A549 cells.
Western blot (WB) analysis of LAT antibody (Cat.-No.: AP06533PU-N) in extracts from NIH/3T3 cells treated with 293 UV 5'.
Western blot (WB) analysis of LAT antibody (Cat.-No.: AP21126PU-N) in extracts from Jurkat cells.
Immunoperoxidase of monoclonal antibody to LAT on formalin-fixed paraffin-embedded human tonsil tissue. [antibody concentration 5ug/ml]
Detection limit for recombinant GST tagged LAT is approximately 0.03ng/ml as a capture antibody.
Distribution of Lat and NTAL in separate clusters on mast cell plasma membrane sheets.Lat and NTAL were detected on mouse bone marrow-derived mast cells ( BMMC ; A ) and RBL rat basophilic leukemia cell line ( B ) by Lat monoclonal antibody, clone LAT-1D1 ( Cat # MAB3623 ) and polyclonal anti-NTAL antibody, followed by 5 or 10 nm gold-conjugated secondary antibodies, respectively.
Flow Cytometry analysis of LAT expression in human peripheral blood lymphocytes ( PBL ) using LAT monoclonal antibody, clone LAT-01 ( Cat # MAB3865 ) (surface markers were stained prior to intracellular staining of human LAT).Panel A : gate on CD4+ cells.Panel B : gate on CD8+ cells.
LAT polyclonal antibody ( Cat # PAB6652 ) ( 0.01 µg/ml ) staining of peripheral blood mononucleocytes lysate ( 35 µg protein in RIPA buffer ) . Primary incubation was 1 hour. Detected by chemiluminescence.
Flow Cytometry analysis of LAT expression in peripheral blood lymphocytes using anti-human LAT (LAT-01) (surface markers were stained prior to intracellular staining of human LAT). Panel A: gate on CD4+ cells. Panel B: gate on CD8+ cells.
Whole cell extract from human peripheral blood mononuclear cells was resolved by electrophoresis, transferred to nitrocellulose and probed with monoclonal anti-LAT Antibody Cat.-No AM33107PU (Clone LAT1111). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and a chemiluminescence system.
Formalin-Fixed Paraffin-Embedded Human Thymus stained with LAT Antibody Cat.-No AM33107PU (Clone LAT1111) at 10 µg/ml after heat-induced antigen retrieval.
Western blot analysis of extracts from Jurkat cells (Lane 1) and Mouse thymocytes (Lane 2) using anti-LAT Antibody Clone 11B.12.
Western blot analysis of LAT (pY191) expression in HeLa PMA-treated (A); Jurkat CD3-treated (B); Raw264.7 PMA-treated (C); PC12 PMA-treated (D) whole cell lysates.
Western blot analysis of LAT (pY255) expression in HEK293T (A); Raw264.7 (B); H9C2 (C) whole cell lysates.
Immunoblotting of 10e6 normal peripheral human blood cells (lane 1), Jurkat (lane 2), and C57BL/6 splenocytes (lane 3) with 5 ug/mL Anti-Human LAT Purified. Bands were visualized using Anti-Mouse IgG HRP.
Western blot analysis of extracts from 293 cells, using LAT (Ab-255) Antibody.The lane on the right is treated with the synthesized peptide.
Western blot analysis of extracts from Jurkat cells (lane 1) and mouse thymocytes (lane 2) using anti-LAT, clone 11B.12.
Western blot analysis of extracts of Jurkat cell line, using LAT antibody.
TA302672 (0.01µg/ml) staining of peripheral blood mononucleocytes lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| TA302672 | LAT (C-term) antibody |
||||||
| Goat Polyclonal Antibody against LAT1 | |||||||
 |
Goat | Aff - Purified | Hu, Ms, Rt | E, WB |
0.1 mg /
€360.00
|
||
| OriGene Technologies, Inc. | |||||||
| TA320411 | LAT antibody |
||||||
| Mouse Anti-Human LAT Purified (25 ug) | |||||||
 |
Mouse | LAT.10-17 (10-17) | Purified | Hu | IP, WB |
25 µg /
€175.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA326210 | LAT antibody |
||||||
| Rabbit polyclonal LAT (Ab-255) antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA327925 | LAT antibody |
||||||
| Mouse Monoclonal anti-LAT Antibody | |||||||
 |
Mouse | IgG1 | 11B.12 | Purified | Hu, Ms | IP, WB |
0.1 mg /
€230.00
|
| OriGene Technologies, Inc. | |||||||
| TA332815 | LAT antibody |
||||||
| Rabbit anti-LAT Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu |
0.1 mg /
€335.00
|
||
| OriGene Technologies, Inc. | |||||||
| AM20572PU-N | LAT antibody |
||||||
 |
Mouse | IgG1 | LAT.10-17 (10-17) | Aff - Purified | Hu | IP, P, WB |
50 µg /
€425.00
|
| OriGene Technologies GmbH | |||||||
 +2 additional images |
|||||||
| AP06532PU-N | LAT antibody |
||||||
 |
Rabbit | Aff - Purified | Hu, Ms | WB |
0.1 mg /
€370.00
|
||
| OriGene Technologies GmbH | |||||||
| AP06533PU-N | LAT antibody |
||||||
 |
Rabbit | Aff - Purified | Hu, Ms, Rt | WB |
0.1 mg /
€370.00
|
||
| OriGene Technologies GmbH | |||||||
| AP21126PU-N | LAT antibody |
||||||
 |
Rabbit | Aff - Purified | Hu | WB |
0.1 mg /
€370.00
|
||
| OriGene Technologies GmbH | |||||||
| SM3119P | LAT antibody |
||||||
 |
Mouse | IgG1 | LAT-01 | Purified | Hu | F, IP, WB |
0.1 mg /
€240.00
|
| OriGene Technologies GmbH | |||||||
Lysates
| Catalog No. | ||
|---|---|---|
| LY423103 | LAT overexpression lysate |
|
 |
0.1 mg /
€295.00
|
|
| OriGene Technologies, Inc. | ||
| LY425376 | LAT overexpression lysate |
|
|
0.1 mg /
€295.00
|
|
| OriGene Technologies, Inc. |
Mouse Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| MR202998L2V | Lenti ORF particles, Lat (GFP-tagged) - Mouse linker for activation of T cells (Lat), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€930.00
|
|
| OriGene Technologies, Inc. | ||
| MR202998L1V | Lenti ORF particles, Lat (Myc-DDK-tagged) - Mouse linker for activation of T cells (Lat), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€830.00
|
|
| OriGene Technologies, Inc. | ||